Regenerative Medical Technology Group Net Profit Margin Growth & History (RMTG)
Regenerative Medical Technology Group's net profit margin was −153.18% for fiscal 2025.
View full Regenerative Medical Technology Group company overviewRegenerative Medical Technology Group annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −153.18% | −17.74 pp |
| 2024 | 2024-12-31 | −135.43% | +271.78 pp |
| 2023 | 2023-12-31 | −407.21% | −47.34 pp |
| 2022 | 2022-12-31 | −359.87% | +2582.55 pp |
| 2021 | 2021-12-31 | −2,942.42% | +7761.05 pp |
| 2020 | 2020-12-31 | −10,703.47% | −2368.28 pp |
| 2019 | 2019-12-31 | −8,335.20% | −4229.59 pp |
| 2018 | 2018-12-31 | −4,105.61% | −2816.30 pp |
| 2017 | 2017-12-31 | −1,289.31% | — |
Regenerative Medical Technology Group quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −72.23% | +74.58 pp |
| Q1 2026 | 2026-03-31 | −33.20% | +22.51 pp |
| Q4 2025 | 2025-12-31 | −79.83% | −37.59 pp |
| Q3 2025 | 2025-09-30 | −368.79% | −278.85 pp |
| Q2 2025 | 2025-06-30 | −146.81% | +114.95 pp |
| Q1 2025 | 2025-03-31 | −55.71% | +184.31 pp |
| Q4 2024 | 2024-12-31 | −42.24% | −0.65 pp |
| Q3 2024 | 2024-09-30 | −89.95% | +815.57 pp |
| Q2 2024 | 2024-06-30 | −261.76% | +300.07 pp |
| Q1 2024 | 2024-03-31 | −240.02% | −27.57 pp |
| Q4 2023 | 2023-12-31 | −41.59% | +133.66 pp |
| Q3 2023 | 2023-09-30 | −905.52% | −539.90 pp |
| Q2 2023 | 2023-06-30 | −561.83% | −60.00 pp |
| Q1 2023 | 2023-03-31 | −212.45% | +348.88 pp |
| Q4 2022 | 2022-12-31 | −175.26% | +446.46 pp |
| Q3 2022 | 2022-09-30 | −365.62% | +5642.21 pp |
| Q2 2022 | 2022-06-30 | −501.83% | +5370.94 pp |
| Q1 2022 | 2022-03-31 | −561.33% | +10069.03 pp |
| Q4 2021 | 2021-12-31 | −621.71% | −213973.92 pp |
| Q3 2021 | 2021-09-30 | −6,007.83% | +54323.86 pp |
| Q2 2021 | 2021-06-30 | −5,872.77% | +5905.20 pp |
| Q1 2021 | 2021-03-31 | −10,630.36% | −3154.45 pp |
| Q4 2020 | 2020-12-31 | 213,352.21% | +234964.60 pp |
| Q3 2020 | 2020-09-30 | −60,331.69% | −32447.73 pp |
| Q2 2020 | 2020-06-30 | −11,777.97% | −52696.33 pp |
| Q1 2020 | 2020-03-31 | −7,475.91% | +15039.97 pp |
| Q4 2019 | 2019-12-31 | −21,612.39% | −10396.86 pp |
| Q3 2019 | 2019-09-30 | −27,883.96% | −22509.17 pp |
| Q2 2019 | 2019-06-30 | 40,918.36% | +40534.58 pp |
| Q1 2019 | 2019-03-31 | −22,515.88% | −21735.16 pp |
| Q4 2018 | 2018-12-31 | −11,215.53% | — |
| Q3 2018 | 2018-09-30 | −5,374.79% | — |
| Q2 2018 | 2018-06-30 | 383.79% | — |
| Q1 2018 | 2018-03-31 | −780.72% | — |
Regenerative Medical Technology Group net profit margin trends
Over the last five fiscal years, Regenerative Medical Technology Group's net profit margin increased from −10,703.47% to −153.18%, a change of +10550.30 percentage points. The latest reported quarter, Q2 2026, shows −72.23%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenerative Medical Technology Group source filings ↗